Uniqure (NASDAQ:QURE) Announces Earnings Results

Uniqure (NASDAQ:QURE) issued its earnings results on Thursday. The biotechnology company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.31), MarketWatch Earnings reports. Uniqure had a negative net margin of 2,553.30% and a negative return on equity of 42.00%. The company had revenue of $1.54 million during the quarter, compared to analyst estimates of $17.87 million.

QURE traded up $2.34 during trading on Friday, hitting $41.73. 726,949 shares of the company’s stock were exchanged, compared to its average volume of 507,709. Uniqure has a fifty-two week low of $36.20 and a fifty-two week high of $76.69. The stock has a market cap of $1.85 billion, a P/E ratio of -13.29 and a beta of 1.24. The business’s 50 day moving average is $49.97 and its two-hundred day moving average is $55.53. The company has a quick ratio of 12.89, a current ratio of 12.89 and a debt-to-equity ratio of 0.12.

In related news, insider Robert Gut sold 26,875 shares of Uniqure stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $70.00, for a total transaction of $1,881,250.00. Also, CEO Matthew C. Kapusta sold 7,501 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $66.04, for a total value of $495,366.04. Following the sale, the chief executive officer now owns 307,332 shares of the company’s stock, valued at approximately $20,296,205.28. The disclosure for this sale can be found here. Insiders sold 40,002 shares of company stock worth $2,614,652 over the last ninety days. Insiders own 2.66% of the company’s stock.

Several equities research analysts recently commented on the stock. Robert W. Baird upgraded shares of Uniqure from a “neutral” rating to an “outperform” rating and cut their target price for the stock from $58.00 to $57.00 in a research report on Friday. Chardan Capital cut their price target on shares of Uniqure from $105.00 to $80.00 and set a “buy” rating on the stock in a report on Thursday, June 25th. Wells Fargo & Co downgraded Uniqure from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $90.00 to $56.00 in a report on Thursday, June 25th. Stifel Nicolaus cut their price objective on Uniqure from $86.00 to $78.00 and set a “buy” rating on the stock in a research note on Thursday, June 25th. They noted that the move was a valuation call. Finally, ValuEngine cut shares of Uniqure from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $73.92.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Featured Article: What is the accumulation/distribution indicator?

Earnings History for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.